



TRANS TASMAN RADIATION ONCOLOGY GROUP LIMITED  
ABN 451 326 722 92

Financial Report  
For the Year Ended  
31 December 2019

## CONTENTS

Responsible Persons' Report.....	1
Auditor's Independence Declaration.....	6
Independent Audit Report.....	7
Responsible Entity Declaration.....	9
Statement of Surplus or Deficit and Other Comprehensive Income.....	10
Statement of Financial Position.....	11
Statement of Changes in Funds.....	12
Statement of Cash Flows.....	13
Notes to the Financial Statements.....	14

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Responsible Persons Report 31 December 2019

The Responsible Persons of Trans Tasman Radiation Oncology Group Limited present their report for the financial year ended 31 December 2019.

### 1. General information

#### Responsible Persons

The names of the responsible persons in office at any time during, or since the end of, the year are:

<b>Names</b>	<b>Position</b>
Dr Giuseppe Sasso	President
A/Prof Purnima Sundaresan	Full Member Director
Dr Fiona Hegi-Johnson	Full Member Director
Prof Annette Haworth	Full Member Director
Professor Trevor Leong	Scientific Committee Chair
Mr Robert Ferguson	Independent Consumer Representative
Dr Tim Kuypers	Independent Director
Denis Byron	Independent Director
Dr Madhavi Chilkuri	RANZCR Director
A/Prof Farshad Foroudi	President (until March 2019)

Responsible Persons have been in office since the start of the financial year to the date of this report unless otherwise stated.

#### Company secretary

The following person held the position of Company Secretary at the end of the financial year:

Susan Goode has been the Company Secretary since October 2019 and is also the Chief Executive Officer of the Company.

#### Principal activities

The principal activities of Trans Tasman Radiation Oncology Group Limited during the financial year were;

- (i) carrying out investigator-driven research in radiation oncology,
- (ii) fostering optimal patient care through maintenance of standards and through independent clinical research trials,
- (iii) fostering regional co-operation between all radiation oncologists in Australia and New Zealand and specifically to promote co-ordinated multi-institution research endeavours, and
- (iv) promoting the highest ethical standard of care and research including quality assurance.

No significant changes in the nature of the Company's activities occurred during the financial year.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Responsible Persons Report

31 December 2019

### 1. General information

#### Short and long term objectives

The Company has established short and long term objectives as outlined in the Company's strategic plan which is reviewed on a quarterly basis. These objectives are both financial and non-financial and are aimed at creating a sustainable business model for researching radiotherapy as a treatment for cancers. Key performance indicators for the business, which roll down to senior management team, have also been established.

#### Members guarantee

Trans Tasman Radiation Oncology Group Limited is a company limited by guarantee. In the event of, and for the purpose of winding up of the Company, the amount capable of being called up from each member and any person or association who ceased to be a member in the year prior to the winding up, is limited to \$10, subject to the provisions of the Company's constitution.

At 31 December 2019 the collective liability of members was \$1,950 (2018 \$1,940).

### 2. Business review

#### Operating results

The surplus of the Company amounted to \$18,526 (2018: deficit of \$(44,280))

### 3. Other items

#### Significant changes in state of affairs

There have been no significant changes in the state of affairs of the Company during the year.

#### After balance date events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations or the state of affairs of the Company in future financial years.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Responsible Persons Report 31 December 2019

### Information on the Responsible Persons

Dr Giuseppe Sasso	President
Qualifications	MChB, FRANZCR
Experience	Clinical Director Radiation Oncology, Northern Regional Cancer and Blood Services, Auckland City Hospital
A/Prof Purnima Sundaresan	Full Member Director
Qualifications	MBBS, BSc (Hons), FRANZCR, PhD
Experience	Consultant Radiation Oncologist Blacktown and Westmead Hospitals. RANZCR FRO Research Committee. Chair TROG Publications Committee. Associate Editor, Journal of Medical Imaging and Radiation Oncology.
Special Responsibilities	TROG 2020 ASM Co-convenor
Dr Fiona Hegi-Johnson	Full Member Director
Qualifications	MBBS (Hons 1), BSc. Med (Hons)
Experience	Radiation Oncologist, Breast, Lung & Sabre Service, Peter MacCallum Cancer Centre. Radiation Oncology Centres, Sydney Adventist Hospital Wahroonga. Chair, TROG Thoracic Oncology Group.
Special Responsibilities	Finance, Audit & Risk Management Committee
Prof Annette Haworth	Full Member Director
Qualifications	FACPSEM, PhD, MSc, BSc (Hons)
Experience	Professor of Medical Physics and Director, Institute of Medical Physics. 20 years clinical medical physics experience. Affiliate academic positions with the University of Melbourne and RMIT University
Professor Trevor Leong	Scientific Committee Chair
Qualifications	MBBS, MD, FRANZCR
Experience	Radiation Oncologist and immediate Past Director, Division of Radiation Oncology, Peter MacCallum Cancer Centre, Director AGITG, Company Secretary AGITG.
Mr Robert Ferguson	Independent Consumer Representative
Qualifications	BA (Psychology), M Counselling
Experience	Consumer Advocate, St Vincent's Hospital. NSW Cancer Council Telephone support Group co-facilitator. Chairman, Muscular Dystrophy Foundation Australia; President, Muscular Dystrophy NSW. Member, Macquarie University Cancer Research Consumer Advisory Group. Cancer Council of Victoria Optimum Cancer Pathway Governance Committee. Director, Colliers International.
Special Responsibilities	Finance, Audit & Risk Management Committee

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Responsible Persons Report 31 December 2019

### Information on the Responsible Persons

Dr Tim Kuypers	Independent Director
Qualifications	GAICD, PhD Economics, ACCA Diploma in Accounting and Finance
Experience	Special Advisor HoustonKemp Economists. Member of Metro Trains Melbourne Board Safety Committee. Experienced non-executive director and senior executive. Significant expertise in highly regulated industries such a health, transport and telecommunications.
Special Responsibilities	Finance, Audit & Risk Management Committee Chair
Denis Byron	Independent Director
Qualifications	BComm, CPA
Experience	Experienced non-executive director, CEO and senior executive. Significant expertise in highly regulated industries such as health. Certified Public Accountant since 1979 awarded Fellow status in 2010.
Special Responsibilities	Finance, Audit & Risk Management Committee
Dr Madhavi Chilkuri	RANZCR Director
Qualifications	BSc, MBBS, MD, FRANZCR
Experience	Radiation oncologist Townsville Cancer Centre, Adjunct Senior Lecturer James Cook University QLD. Dean of the Faculty of Radiation Oncology and Director, Royal Australian and New Zealand College of Radiologists. Member of the Australia Institute of Company Directors.
A/Prof Farshad Foroudi	President (until March 2019)
Qualifications	MBBS (Hon 1), MPA, DMedSc, FRANZCR
Experience	Director of Radiation Oncology, Austin Health

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Responsible Persons Report 31 December 2019

### Meetings of Responsible Persons

During the financial year, 6 meetings of Responsible Persons (including committees of responsible persons) were held. Attendances by each responsible person during the year were as follows:

	Directors' Meetings		Finance, Audit & Risk Management Committee	
	Number eligible to attend	Number attended	Number eligible to attend	Number attended
Dr Giuseppe Sasso	6	6	-	-
A/Prof Purnima Sundaresan	6	6	-	-
Dr Fiona Hegi-Johnson	6	6	5	5
Prof Annette Haworth	3	3	-	-
Professor Trevor Leong	6	6	-	-
Mr Robert Ferguson	6	5	5	5
Dr Tim Kuypers	6	6	5	5
Denis Byron	4	3	3	3
Dr Madhavi Chilkuri	6	5	-	-
A/Prof Farshad Foroudi	1	1	-	-

### Indemnification and insurance of officers and auditors

The Company has paid premiums to insure each of the Directors against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of Director of the Company, other than conduct involving a wilful breach of duty in relation to the Company. The amount of the premium is not disclosed due to the terms of the insurance contracts and to protect commercially sensitive information of the Company.

### Auditor's independence declaration

The lead auditor's independence declaration in accordance with subdivision 60-C of the *Australian Charities and Not-for-profits Commission Act 2012*, for the year ended 31 December 2019 has been received and can be found on page 6 of the financial report.

Signed in accordance with a resolution of the Board of Directors:

Director:  .....  
Dr Giuseppe Sasso

Director:  .....  
Dr Tim Kuypers

Dated 4 March 2020

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Auditors Independence Declaration to the Directors of Trans Tasman Radiation Oncology Group Limited

I declare that, to the best of my knowledge and belief, during the year ended 31 December 2019, there have been:

- (i) no contraventions of the auditor independence requirements as set out in the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

*Cutcher & Neale Assurance Pty Ltd*

Cutcher & Neale Assurance Pty Ltd  
(An authorised audit company)



M.J. O'Connor  
Director

27 February 2020

Newcastle



# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Independent Audit Report to the members of Trans Tasman Radiation Oncology Group Limited

### Report on the Audit of the Financial Report

#### Opinion

We have audited the financial report of Trans Tasman Radiation Oncology Group Limited (the Company), which comprises the statement of financial position as at 31 December 2019, the statement of surplus or deficit and other comprehensive income, the statement of changes in funds and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the responsible entity declaration.

In our opinion, the accompanying financial report of the Company is in accordance with the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) giving a true and fair view of the Company's financial position as at 31 December 2019 and of its financial performance for the year ended; and
- (ii) complying with Australian Accounting Standards and division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

#### Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Australian Charities and Not-for-profits Commission Act 2012*, which has been given to the Directors of the Company, would be in the same terms if given to the Directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Other Information

The Directors are responsible for the other information. The other information obtained at the date of this auditor's report was limited to the directors report.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

7

Newcastle 25 Bolton Street (PO Box 694) Newcastle NSW 2300 T 02 4928 8500 F 02 4926 1971 E [cnmail@cutcher.com.au](mailto:cnmail@cutcher.com.au)  
Sydney Suite 1102, Level 11, 20 Berry Street (PO Box 281) North Sydney NSW 2059 T 02 9923 1817

Liability Limited by a scheme approved under Professional Standards Legislation. Cutcher & Neale Assurance Pty Ltd ABN 37 126 556 330

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Independent Audit Report to the members of Trans Tasman Radiation Oncology Group Limited

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibilities of Directors for the Financial Report


The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Australian Charities and Not-for-profits Commission Act 2012* and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

### Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: [http://www.auasb.gov.au/auditors\\_responsibilities/ar4.pdf](http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf). This description forms part of our audit report.



Cutcher & Neale Assurance Pty Ltd  
(An authorised audit company)



M. J. O'Connor  
Partner

NEWCASTLE

5 March 2020

8

Newcastle 25 Bolton Street (PO Box 694) Newcastle NSW 2300 T 02 4928 8500 F 02 4926 1971 E [cnmail@cutcher.com.au](mailto:cnmail@cutcher.com.au)  
Sydney Suite 1102, Level 11, 20 Berry Street (PO Box 281) North Sydney NSW 2059 T 02 9923 1817

Liability Limited by a scheme approved under Professional Standards Legislation. Cutcher & Neale Assurance Pty Ltd ABN 37 126556 330

[cutcher.com.au](http://cutcher.com.au)

Innovative thinking. Traditional values.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292


## Responsible Entity Declaration

The Responsible Persons of the Company declare that:

1. The financial statements and notes, as set out on pages 10 to 25, are in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012* and:
  - (a) comply with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*; and
  - (b) give a true and fair view of the financial position as at 31 December 2019 and of the performance for the year ended on that date of the Company.
2. In the Responsible Persons' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Responsible Persons.

Responsible Person

.....  
  
Dr Giuseppe Sasso

Responsible Person

.....  
  
Dr Tim Kuypers

Dated: ..... 4/3/2020 .....

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Statement of Surplus or Deficit and Other Comprehensive Income For the Year Ended 31 December 2019

		2019	2018
	Note	\$	\$
Revenue	2	2,385,325	2,479,567
Other income	2	78,291	74,123
Employee benefits expense		(1,514,154)	(1,641,647)
Depreciation and amortisation expense	3(a)	(60,730)	(51,040)
Annual Scientific Meeting		(318,743)	(287,968)
Administration and other expenses		(551,463)	(617,315)
<b>Surplus/(deficit) before income tax</b>		<b>18,526</b>	<b>(44,280)</b>
Income tax expense	1(f)	-	-
<b>Surplus/(deficit) after income tax</b>		<b>18,526</b>	<b>(44,280)</b>
Other comprehensive income		-	-
<b>Total comprehensive income/(expense) for the year</b>		<b>18,526</b>	<b>(44,280)</b>

The accompanying notes form part of these financial statements.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Statement of Financial Position As At 31 December 2019

	Note	2019 \$	2018 \$
<b>ASSETS</b>			
CURRENT ASSETS			
Cash and cash equivalents	4	2,962,978	2,575,411
Trade and other receivables	5	1,133,037	422,325
Other assets		127,559	121,851
TOTAL CURRENT ASSETS		<u>4,223,574</u>	<u>3,119,587</u>
NON-CURRENT ASSETS			
Property, plant and equipment	6	50,496	34,974
Intangible assets	7	110,212	107,379
TOTAL NON-CURRENT ASSETS		<u>160,708</u>	<u>142,353</u>
TOTAL ASSETS		<u>4,384,282</u>	<u>3,261,940</u>
<b>LIABILITIES</b>			
CURRENT LIABILITIES			
Trade and other payables	8	219,367	110,797
Employee benefits	10	159,451	147,733
Other liabilities	9	2,934,168	1,944,188
TOTAL CURRENT LIABILITIES		<u>3,312,986</u>	<u>2,202,718</u>
NON-CURRENT LIABILITIES			
Employee benefits	10	18,403	24,855
TOTAL NON-CURRENT LIABILITIES		<u>18,403</u>	<u>24,855</u>
TOTAL LIABILITIES		<u>3,331,389</u>	<u>2,227,573</u>
NET ASSETS		<u>1,052,893</u>	<u>1,034,367</u>
<b>FUNDS</b>			
Accumulated surplus		<u>1,052,893</u>	<u>1,034,367</u>
TOTAL FUNDS		<u>1,052,893</u>	<u>1,034,367</u>

The accompanying notes form part of these financial statements.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Statement of Changes in Funds For the Year Ended 31 December 2019

**2019**

	<b>Accumulated surplus \$</b>
<b>Balance at 1 January 2019</b>	<u>1,034,367</u>
Total comprehensive income	<u>18,526</u>
<b>Balance at 31 December 2019</b>	<u>1,052,893</u>

**2018**

	<b>Accumulated surplus \$</b>
<b>Balance at 1 January 2018</b>	<u>1,078,647</u>
Total comprehensive income	<u>(44,280)</u>
<b>Balance at 31 December 2018</b>	<u>1,034,367</u>

The accompanying notes form part of these financial statements.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Statement of Cash Flows

For the Year Ended 31 December 2019

	2019	2018
Note	\$	\$
<b>CASH FROM OPERATING ACTIVITIES:</b>		
Receipts from customers	3,165,541	3,674,202
Payments to suppliers and employees	(2,744,302)	(3,163,745)
Interest received	45,414	33,141
Net cash provided by (used in) operating activities	<u>466,653</u>	<u>543,598</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of property, plant and equipment	6(a) (38,546)	(7,807)
Payment for intangible asset	7(a) (40,540)	(8,720)
Net cash used by investing activities	<u>(79,086)</u>	<u>(16,527)</u>
Net increase (decrease) in cash and cash equivalents held	387,567	527,071
Cash and cash equivalents at beginning of year	<u>2,575,411</u>	<u>2,048,340</u>
Cash and cash equivalents at end of financial year	4 <u>2,962,978</u>	<u>2,575,411</u>

The accompanying notes form part of these financial statements.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

The financial statements are for Trans Tasman Radiation Oncology Group Limited as an individual entity, incorporated and domiciled in Australia. Trans Tasman Radiation Oncology Group Limited is a not for profit Company limited by guarantee.

### 1 Significant Accounting Policies

#### (a) Basis of preparation

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012*.

Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

The financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

#### (b) New Accounting Standards and Interpretations

##### (i) Initial application of AASB 15 and AASB 1058

The Company has applied AASB 15: Revenue from Contracts with Customers (AASB 15) and AASB 1058: Income of Not-for-Profit Entities (AASB 1058) using the cumulative effective method of initially applying AASB 15 and AASB 1058 as an adjustment to the opening balance of equity at 1 January 2019. Therefore, the comparative information has not been restated and continues to be presented under AASB 118: Revenue and AASB 1004: Contributions.

The Company has assessed that there is no material impact on revenue or contract liabilities on application of AASB 15 and AASB 1058 from 1 January 2019.

##### (ii) Initial application of AASB 16

The Company has adopted AASB 16: Leases with a date of initial application of 1 January 2019. As a result, the Company has changed its lease accounting policy as detailed at Note 1(o).

AASB 16 replaces the provisions of AASB 117: Leases and provides a new lessee accounting model. The new model requires a lessee to recognise a right-of-use asset and lease liability for all leases with a term of more than 12 months, unless the underlying asset is of low value. Lessor accounting remains the same under AASB 16 when compared to the requirements of AASB 117.

For leases that have significantly below-market terms and conditions principally to enable the Company to further its objectives (commonly known as peppercorn or concessionary leases), the Company has adopted the temporary relief under AASB 2018-8 and measures the right-of-use asset at cost on initial recognition.



# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (c) Comparative figures

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

When the Company applies an accounting policy retrospectively, makes a retrospective restatement or reclassifies items in its financial statements, a statement of financial position as at the beginning of the earliest comparative period will be presented.

#### (d) Revenue and other income

The Company has applied AASB 15: *Revenue from Contracts with Customers* (AASB 15) and AASB 1058: *Income of Not-for-Profit Entities* (AASB 1058) using the cumulative effective method of initially applying AASB 15 and AASB 1058 as an adjustment to the opening balance of equity at 1 January 2019. Therefore, the comparative information has not been restated and continues to be presented under AASB 118: *Revenue* and AASB 1004: *Contributions*. The details of accounting policies under AASB 118 and AASB 1004 are disclosed separately since they are different from those under AASB 15 and AASB 1058, and the impact of those changes is disclosed in Note 1.

#### *In the current year*

#### **Membership subscriptions**

Membership and Facility Alliance subscriptions are recognised on a proportionate basis over the period of the subscription. The amount attributed to the period subsequent to balance date is recorded as a liability.

#### **Clinical Research and Radiation Therapy Quality Assurance Services**

The Company earns revenue from provision of professional services, including the coordination of cancer clinical trials research and providing quality assurance for clinical trials to ensure protocol compliance and trial quality. Contracts with customers include fixed fee arrangements, unconditional fee for service arrangements and variable fee arrangements.

For fixed fee arrangements, revenue is recognised based on the stage of completion with reference to the actual service provided as a proportion of the total services expected to be provided under the contract. The stage of completion is tracked on a contract by contract basis using a milestone-based approach.

Estimates of revenue, costs or extent or progress toward completion are revised if circumstances change. Any resulting increases or decreases in estimated revenues or costs are reflected in surplus or deficit in the period to which the circumstances that give rise to the revision become known by management.

In fee for service contracts, revenue is recognised up to the amount of fees the Company is entitled to invoice for services performed to date based on contracted rates.

The Company estimates fees for variable fee arrangements using a most likely amount approach on a contract by contract basis. Management makes a detailed assessment of the amount of revenue expected to be received and variable consideration is included in revenue only to the extent that it is highly probable that the amount will not be subject to significant reversal.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (d) Revenue and other income

##### Annual Scientific Meeting

The Company organises and hosts a national conference each year for Radiation Oncologists, Radiation Therapists, Medical Physicists and clinical trials personnel.

Revenue from the Annual Scientific Meeting is recognised upon completion of the conference, as this is when performance obligations have been satisfied.

##### Operating grants, donations and bequests

When the Company receives operating grant revenue, donations or bequests, it assesses whether the contract is enforceable and has sufficiently specific performance obligations in accordance with AASB 15.

When both these conditions are satisfied, the Company:

- Identifies each performance obligation relating to the grant;
- Recognises a contract liability for its obligations under the agreement; and
- Recognises revenue as it satisfies its performance obligations.

Where the contract is not enforceable or does not have sufficiently specific performance obligations, the Company:

- Recognises the asset received in accordance with the recognition requirements of other applicable Accounting Standards (for example AASB 9, AASB 16, AASB 116 and AASB 138);
- Recognises related amounts (being lease liability, financial instruments, provisions, revenue or contract liability arising from a contract with a customer); and
- Recognises income immediately in surplus or deficit as the difference between the initial carrying amount of the asset and the related amount.

If a contract liability is recognised as a related amount above, the Company recognises income in surplus or deficit when or as it satisfies its obligations under the contract.

##### Capital grants

When the Company receives a capital grant, it recognises a liability for the excess of the initial carrying amount of the financial asset received over any related amounts (being lease liability, financial instruments, provisions, revenue or contract liability arising from a contract with a customer), recognised under other Australian Accounting Standards.

The Company recognises income in surplus or deficit when as the Company satisfies the obligations under the terms of the grant.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (d) Revenue and other income

##### Interest income

Interest income is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

##### *In the comparative year*

Revenue from the rendering of services is recognised upon delivery of the service to the customer.

Membership and Facility Alliance subscriptions are recognised on a proportionate basis over the period of the subscription. The amount attributed to the period subsequent to balance date is recorded as a liability.

Interest income is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

Donations are recognised in the statement of surplus or deficit and other comprehensive income.

Grant revenue is recognised in the statement of surplus or deficit and other comprehensive income when the entity obtains control of the grant, it is probable that the economic benefits gained from the grant will flow to the entity and the amount of the grant can be measured reliably.

When grant revenue is received whereby the entity incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Inkind contributions are recognised on the date of acquisition at fair value as revenue from sponsorship and within the relevant expenditure category in the statement of surplus or deficit and other comprehensive income.

All revenue is stated net of the amount of goods and services tax (GST).

#### (e) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (f) Income tax

No provision for income tax has been raised as the Company is exempt from income tax under Div 50 of the *Income Tax Assessment Act 1997*.

#### (g) Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at call with banks, and other short-term highly liquid investments with original maturities of three months or less which are convertible to a known amount of cash and subject to an insignificant risk of change in value.

#### (h) Property, plant and equipment

Each class of property, plant and equipment is carried at cost or fair value as indicated less, where applicable, any accumulated depreciation and impairment losses.

##### Plant and equipment

Plant and equipment are measured on the cost basis less depreciation and impairment losses. Cost includes expenditure that is directly attributable to the asset.

Plant and equipment that have been contributed at no cost, or for nominal cost are valued and recognised at the fair value of the asset at the date it is acquired.

##### Depreciation

The depreciable amount of all plant and equipment is depreciated on a straight-line basis over the asset's useful life to the Company commencing from the time the asset is held ready for use.

The depreciation rates used for each class of depreciable assets are:

<b>Class of Fixed Asset</b>	<b>Depreciation Rate</b>
Plant and Equipment	20% - 33%
Furniture, Fixtures and Fittings	10%

The assets' residual values, depreciation methods and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the statement of surplus or deficit and other comprehensive income.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (i) Investments and other financial assets

##### *i) Classification*

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income or through profit or loss), and

- those to be measured at amortised cost.

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows.

The Company is using the measured at amortised cost method for all its financial assets, namely trade and other receivables and debt investments, such as "cash invested in term deposit products. Assets measured at amortised cost are financial assets where:

- the business model is to hold assets to collect contractual cash flows; and

- the contractual terms give rise on specified dates to cash flows are solely payments of principal and interest on the principal amount outstanding.

The Company reclassifies debt investments when and only when its business model for managing those assets changes.

##### *ii) Recognition and derecognition*

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the company commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership.

##### *iii) Measurement*

Subsequent to initial recognition, financial assets are carried at amortised costs using the effective interest rate method less provision for impairment.

Interest income and impairment for expected credit losses are recognised in the profit or loss. Gain or loss on derecognition is recognised in profit or loss.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (i) Investments and other financial assets

##### *iv) Impairment*

Impairment of financial assets is recognised on an expected credit loss (ECL) – forward looking - basis for all financial assets measured at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. The Company considers reasonable and supportable information that is relevant and available, including both quantitative and qualitative information and analysis based on the Company's historical experience and informed credit assessment, including forward looking information.

Credit losses are measured as the present value of the difference between the cash flows due to the Company in accordance with the contract and the cash flows expected to be received. This is applied using a probability weighted approach.

#### (j) Intangible Assets

##### **Software**

Software has a finite life and is carried at cost less any accumulated amortisation and impairment losses. It has an estimated useful life of five to ten years.

##### **Amortisation**

Amortisation is recognised in the statement of surplus or deficit and other comprehensive income on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use.

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

#### (k) Trade and other payables

Trade and other payables are carried at amortised cost and represent liabilities for goods and services provided to the Company during the reporting period which remain unpaid at balance date. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

#### (l) Employee benefits

Provision is made for the Company's liability for employee benefits arising from services rendered by employees to the end of the reporting period. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled.

Employee benefits payable later than one year have been measured at their nominal amount. This estimate is not materially different from the present value of the estimated future cash outflows to be made for those benefits.

Contributions are made by the Company to an employee superannuation fund and are charged as expenses when incurred.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 1 Significant Accounting Policies

#### (m) Unexpended grants

The liability for deferred income is the unutilised amounts of grants received on the condition that specified services are delivered or conditions are fulfilled in a future period.

#### (n) Trial funds held

A liability is recognised for trial funds held where ultimate control of the trial funds is vested in the trial chairperson. The Directors have determined that the Company receives no economic benefit from the holding of trial funds, and accordingly no revenue is recognised.

#### (o) Leases

For leases that have significantly below-market terms and conditions principally to enable the Company to further its objectives (commonly known as peppercorn or concessionary leases), the Company has adopted the temporary relief under AASB 2018-8 and measures the right-of-use asset at cost on initial recognition.

The Company currently holds one lease for office premises which is provided at below market terms.

#### (p) Critical accounting estimates and judgements

The Directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

#### Key estimates

##### (i) Impairment of plant and equipment

The Company assesses impairment at the end of the reporting year by evaluating conditions specific to the Company that may be indicative of impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

#### Key judgements

##### (i) Performance obligations under AASB 15

To identify a performance obligation under AASB 15, the promise must be sufficiently specific to be able to determine when the obligation is satisfied. Management exercises judgement to determine whether the promise is sufficiently specific by taking into account any conditions specified in the arrangement, explicit or implicit, regarding the promised goods or services. In making this assessment, management includes the nature, value, quantity and period of transfer related to the goods or services promised.

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 2 Revenue and Other Income

	2019	2018
	\$	\$
Revenue		
- Government grants	512,000	468,000
- Donations and sponsorships	290,287	447,023
- Annual Scientific Meeting	465,909	457,155
- Membership subscriptions	35,329	33,465
- Research services	396,891	564,816
- Facility Alliance memberships	371,150	386,300
- Quality Assurance services	313,759	122,808
Total revenue from operating activities	<u>2,385,325</u>	<u>2,479,567</u>
Other Income		
- Interest income	45,414	33,141
- Other income	32,877	40,982
Total revenue from non operating activities	<u>78,291</u>	<u>74,123</u>

### 3 Surplus for the Year

(a) The result for the year includes the following specific expenses:

Depreciation and Amortisation		
Depreciation - plant and machinery	23,024	20,054
Intangible assets	37,707	30,986
Total Depreciation and Amortisation	<u>60,731</u>	<u>51,040</u>

### 4 Cash and Cash Equivalents

Cash at bank	1,949,387	1,516,571
Payroll clearing account	159,037	110,273
Trial funds held in trust	(a) 854,554	948,567
	<u>2,962,978</u>	<u>2,575,411</u>

#### (a) Trial funds held in trust

Trial funds held in trust as disclosed in Note 9.

### 5 Trade and Other Receivables

CURRENT		
Trade receivables	1,133,037	422,325
	<u>1,133,037</u>	<u>422,325</u>



# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 6 Property, Plant and Equipment

	2019	2018
	\$	\$
PLANT AND EQUIPMENT		
Plant and equipment		
At cost	203,123	169,550
Accumulated depreciation	(162,768)	(144,728)
Total plant and equipment	<u>40,355</u>	<u>24,822</u>
Furniture, fixture and fittings		
At cost	19,628	17,845
Accumulated depreciation	(9,487)	(7,693)
Total furniture, fixture and fittings	<u>10,141</u>	<u>10,152</u>
Total property, plant and equipment	<u><u>50,496</u></u>	<u><u>34,974</u></u>

#### (a) Movements in Carrying Amounts

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial year:

	Plant & Equipment	Furniture, Fixtures & Fittings	Total
	\$	\$	\$
Balance at the beginning of year	24,822	10,152	34,974
Additions	36,148	2,398	38,546
Depreciation expense	(20,615)	(2,409)	(23,024)
Closing value at 31 December 2019	<u><u>40,355</u></u>	<u><u>10,141</u></u>	<u><u>50,496</u></u>

### 7 Intangible Assets

	2019	2018
	\$	\$
Cost	251,876	211,336
Accumulated amortisation	(141,664)	(103,957)
Total Intangibles	<u><u>110,212</u></u>	<u><u>107,379</u></u>

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 7 Intangible Assets

#### (a) Movements in carrying amounts of intangible assets

	\$
<b>Year ended 31 December 2019</b>	
Balance at the beginning of the year	107,379
Additions	40,540
Amortisation	<u>(37,707)</u>
<b>Closing value at 31 December 2019</b>	<b><u>110,212</u></b>

### 8 Trade and Other Payables

	2019	2018
	\$	\$
CURRENT		
Unsecured liabilities		
Trade payables	43,777	38,104
GST payable	127,965	64,893
Sundry payables and accrued expenses	<u>47,625</u>	7,800
	<b><u>219,367</u></b>	<b><u>110,797</u></b>

### 9 Other Liabilities

CURRENT		
Contract liability - grant funding	134,317	174,000
Trial funds held	856,628	948,567
Contract liabilities - trial services	<u>1,943,223</u>	821,621
	<b><u>2,934,168</u></b>	<b><u>1,944,188</u></b>

### 10 Employee Benefits

CURRENT		
Provision for employee benefits	136,862	129,037
Long service leave	<u>22,589</u>	18,696
	<b><u>159,451</u></b>	<b><u>147,733</u></b>
NON-CURRENT		
Long service leave	<u>18,403</u>	24,855

# Trans Tasman Radiation Oncology Group Limited

ABN 45 132 672 292

## Notes to the Financial Statements For the Year Ended 31 December 2019

### 11 Members' Guarantee

The Company is incorporated under the Corporations Act 2001 and is a Company limited by guarantee. If the Company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstandings and obligations of the Company. At 31 December 2019 the number of members was 195 (2018: 194).

### 12 Related Parties

Trans Tasman Radiation Oncology Group Limited performs trial co-ordination and quality assurance services for a Trial that is chaired by Dr Farshad Forouhi (Director). Total receipts in 2019 amounted to \$140,922 (2018: \$187,883).

Trans Tasman Radiation Oncology Group Limited performs trial co-ordination and quality assurance services for a Trial that is chaired by Dr Fiona Hegi-Johnson (Director). Total receipts in 2019 amounted to \$138,289 (2018: \$11,661).

### 13 Key Management Personnel Remuneration

The totals of remuneration paid to the key management personnel of Trans Tasman Radiation Oncology Group Limited during the year are as follows:

	2019	2018
	\$	\$
Short-term employee benefits	175,672	156,707
Post-employment benefits	16,555	17,690
Termination benefits	-	40,430
	<u>192,227</u>	<u>214,827</u>

### 14 Events after the end of the Reporting Period

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.